Retraction
The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
Paper Information
Record ID:
37210
Journal:
Publication Date:
May 08, 2018
Retraction Date:
March 07, 2022
(3.7 years years ago)
Subjects:
Institutions:
- Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland)
- Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland)
- Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland)
Country:
🇨🇳 ChinaArticle Type:
Publisher:
International Scientific Information, Inc
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (17)
17
Total Citations3
Post-Retraction(17.6%)
13
Pre-Retraction1
Same DayPost-Retraction Citation Analysis
0
Within 30 days
2
Within 1 year
1
After 2+ years
1192
Days since retraction (latest)
Advances in lenvatinib monotherapy and combination therapies in anaplastic thyroid cancer (Review)
Lisha Xu, Weidong Zhang, Yinchun Wang et al. (7 authors)
Oncology Letters
Open Access
Published: Jun 2025
1192 days after retraction
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Qingfang Li, Yan Tie, Aqu Alu et al. (5 authors)
Signal Transduction and Targeted Therapy
Open Access
Published: Jan 2023
155 citations
155 citations
315 days after retraction
Targeted therapy and drug resistance in thyroid cancer
Yujie Zhang, Zhichao Xing, Tianyou Liu et al. (8 authors)
European Journal of Medicinal Chemistry
Published: May 2022
32 citations
32 citations
83 days after retraction
Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib
Hao Song, Jinna Zhang, Ning Liang et al. (7 authors)
Medical Science Monitor
Open Access
Published: Mar 2022
Same day as retraction
miR-16 Inhibits Extracellular Signal-Regulated Kinases (ERK) Mitogen-Activated Protein Kinases (MAPK) Signaling to Affect Epithelial-Mesenchymal Transition (EMT) and Invasion of Glioma Cells
Peng Sun, Duojiao Fan, Jing Cao et al. (7 authors)
Journal of Biomaterials and Tissue Engineering
Published: Jan 2022
53 days before retraction
Treatment Effect of Combining Lenvatinib and Vemurafenib for <i>BRAF</i> Mutated Anaplastic Thyroid Cancer
Chae Moon Hong, Ji Min Oh, Prakash Gangadaran et al. (5 authors)
International Journal of Thyroidology
Open Access
Published: Nov 2021
1 citation
1 citation
97 days before retraction
New Insights into the Link between Melanoma and Thyroid Cancer: Role of Nucleocytoplasmic Trafficking
Mourad Zerfaoui, Titilope M. Dokunmu, Eman A. Toraih et al. (6 authors)
Cells
Open Access
Published: Feb 2021
17 citations
17 citations
390 days before retraction
Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS
Ji Min Oh, Byeong‐Cheol Ahn
Theranostics
Open Access
Published: Jan 2021
99 citations
99 citations
430 days before retraction
Tripartite motif‑containing 14 regulates cell proliferation and apoptosis in cervical cancer via the Akt signaling pathway
Wenjing Diao, Caiying Zhu, Qisang Guo et al. (9 authors)
Molecular Medicine Reports
Open Access
Published: Oct 2020
13 citations
13 citations
497 days before retraction
Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation
Evgeny N. Imyanitov, E. Levchenko, Ekatherina Sh. Kuligina et al. (4 authors)
Expert Opinion on Pharmacotherapy
Published: Sep 2020
15 citations
15 citations
550 days before retraction
A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
Yanan Li, Ying Cheng, Maoqi Zhang et al. (11 authors)
iScience
Open Access
Published: Jun 2020
6 citations
6 citations
635 days before retraction
Roles of S100 family members in drug resistance in tumors: Status and prospects
Xin Hua, Hongming Zhang, Jinfang Jia et al. (6 authors)
Biomedicine & Pharmacotherapy
Open Access
Published: Apr 2020
48 citations
48 citations
683 days before retraction
Activating BRAF mutation in sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid gland: two case reports and review of the literature
Jasmine Sukumar, Senthil Sukumar, Darshana Purohit et al. (7 authors)
Journal of Medical Case Reports
Open Access
Published: Dec 2019
16 citations
16 citations
827 days before retraction
Synthesis, antiproliferative activity and DNA/RNA-binding properties of mono- and bis-(1,2,3-triazolyl)-appended benzimidazo[1,2-a]quinoline derivatives
Andrijana Meščić, Nataša Perin, Silvio Jakopec et al. (8 authors)
European Journal of Medicinal Chemistry
Published: Nov 2019
33 citations
33 citations
852 days before retraction
Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics
Yuchen Jin, Min Liu, Ri Sa et al. (6 authors)
Cancer Letters
Published: Oct 2019
19 citations
19 citations
885 days before retraction
BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future Perspectives
Fabiana Crispo, Tiziana Notarangelo, Michele Pietrafesa et al. (8 authors)
Cancers
Open Access
Published: Sep 2019
96 citations
96 citations
901 days before retraction
Synergistic inhibition of MEK/ERK and BRAF V600E with PD98059 and PLX4032 induces sodium/iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells
Honglai Zhang, Dong Chen
Thyroid Research
Open Access
Published: Oct 2018
29 citations
29 citations
1243 days before retraction
Quick Stats
Total Citations:
17
Years Since Retraction:
3.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025